| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
From EPICORE (P.W.F.W.), Emory University School of Medicine, and the Atlanta VAMC Epidemiology and Genetics Section, Atlanta, Ga; National Heart, Lung, and Blood Institute (C.J.O.D.); National Heart, Lung and Blood Institutes Framingham Heart Study (M.P., R.D.A., C.J.O.D.), Framingham Mass; Department of Mathematics (M.P., R.D.A.), Boston University, Boston, Mass; Tufts USDA Nutrition Center (P.J., J.S.), Boston, Mass.
Correspondence to Peter W. F. Wilson, MD, Suite 1 North, Emory University School of Medicine, 1256 Briarcliff Rd, and the Atlanta VAMC Epidemiology and Genetics Section, Atlanta, GA 30306. E-mail peter.wf.wilson{at}emory.edu
Received October 23, 2008; accepted October 23, 2008.
Background— The relationship of circulating levels of high-sensitivity C-reactive protein (CRP) with cardiovascular disease (CVD) risk, particularly with consideration of effects at intermediate levels of risk, has not been fully assessed.
Methods and Results— Among 3006 offspring participants in the Framingham Heart Study free of CVD (mean age, 46 years at baseline), there were 129 hard coronary heart disease (CHD) events and 286 total CVD events during 12 years of follow-up. Cox regression, discrimination with area under the receiver operating characteristic curve, and net reclassification improvement were used to assess the role of CRP on vascular risk. In an age-adjusted model that included both sexes, the hazard ratios for new hard CHD and total CVD were significantly associated with higher CRP levels. Similar analyses according to increasing homocysteine level showed significant protective associations for hard CHD but not for total CVD. In multivariable analyses that included age, sex, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, diabetes mellitus, current smoking, hypertension treatment, and homocysteine, the log CRP level remained significantly related to development of hard CHD and total CVD and provided moderate improvement in the discrimination of events. The net reclassification improvement when CRP was added to traditional factors was 5.6% for total CVD (P=0.014) and 11.8% for hard CHD (P=0.009).
Conclusions— Circulating levels of CRP help to estimate risk for initial cardiovascular events and may be used most effectively in persons at intermediate risk for vascular events, offering moderate improvement in reclassification of risk.
Key Words: epidemiology inflammation risk factors statistics
Related Article
Circ Cardiovasc Qual Outcomes 2008 1: 92-97.
This article has been cited by other articles:
![]() |
M. J. Pencina, R. B. D'Agostino Sr, M. G. Larson, J. M. Massaro, and R. S. Vasan Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study Circulation, June 23, 2009; 119(24): 3078 - 3084. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Cook and P. M Ridker Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures Ann Intern Med, June 2, 2009; 150(11): 795 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mora, K. Musunuru, and R. S. Blumenthal The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines Clin. Chem., February 1, 2009; 55(2): 219 - 228. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M Ridker C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 209 - 215. [Full Text] [PDF] |
||||
![]() |
R. S Vasan Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness Int. J. Epidemiol., February 1, 2009; 38(1): 231 - 234. [Full Text] [PDF] |
||||
![]() |
H. M. Krumholz Outcomes Research: Myths and Realities Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
C-Reactive Protein and the Framingham Risk Score Journal Watch Cardiology, November 26, 2008; 2008(1126): 3 - 3. [Full Text] |
||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |